Navigation Links
Elan ADS Holders Decisively Vote Against Theravance And AOP Transactions
Date:6/13/2013

nd any impact that those matters may have on Elan, the Elan Group, RP Management or Royalty Pharma following the Further Increased Offer; statements concerning any future Irish, US or other economic environment or performance; statements about strategic goals, competition, regulation, regulatory approvals, dispositions and consolidation or technological or regulatory developments; and statements of assumptions underlying such statements.

Forward looking statements only speak as of the date on which they are made, and the events discussed in this announcement may not occur. Subject to compliance with applicable law and regulation, Royalty Pharma is not under any obligation to update publicly or revise forward looking statements, whether as a result of new information, future events or otherwise.

Rule 8 - Dealing Disclosure Requirements

Under the provisions of Rule 8.3 of the Irish Takeover Rules, if any person is, or becomes, "interested" (directly or indirectly) in 1% or more of any class of "relevant securities" of Elan, all "dealings" in any "relevant securities" of Elan (including by means of an option in respect of, or a derivative referenced to, any such "relevant securities") must be publicly disclosed by not later than 3.30 pm (Irish time) on the "business day" following the date of the relevant transaction. This requirement will continue until the date on which the Further Increased Offer becomes or is declared unconditional as to acceptances or lapses or is otherwise withdrawn or on which the Offer Period otherwise ends. If two or more persons co-operate on the basis of any agreement, either express or tacit, either oral or written, to acquire an "interest" in "relevant securities" of Elan, they will be deemed to be a single person for the purpose of Rule 8.3 of the Irish Takeover Rules.

Under the provisions of Rule 8.1 of the Irish Takeover Rules, all "dealings" in "relevant securities" of Elan by Elan or Royalty Pharma, or by
'/>"/>

SOURCE Royalty Pharma
Copyright©2012 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9 10 11

Related medicine technology :

1. Omthera Pharmaceuticals Announces Record Date and Meeting Date for Special Meeting of Stockholders
2. Royalty Pharma Urges Elan Shareholders to Vote AGAINST ALL FOUR Elan Resolutions Today
3. CVBT Shareholders Vote for Change
4. Cytos Invites to the Annual Shareholders Meeting 2013
5. Accelerate Diagnostics Announces Plans For Rights Offering To Stockholders
6. Omthera Pharmaceuticals, Inc. Stockholders Seeking More Money, Information in Buyout Should Contact Deans & Lyons Law Firm
7. Royalty Pharma Recommends Elan Shareholders vote "NO" on each of the Elan Resolutions at the Elan extraordinary general meeting
8. SHAREHOLDER ALERT: Pomerantz Law Firm Reminds Shareholders with Losses on Their Investment in AMAG Pharmaceuticals, Inc. of Class Action Lawsuit Investigation - AMAG
9. 3SBio Inc. Announces Shareholders Approval of the Amended Merger Agreement
10. Medifirst Solutions, Inc. Announces Update To Shareholders
11. LCA-Vision Reports on Annual Meeting of Stockholders
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/15/2014)... , Jan. 15, 2014  Celsion Corporation (the "Company") ... it has received commitments from institutional investors to ... the Company,s common stock in an at-the-market registered ... fund. The Company entered into definitive ... the Company agreed to sell an aggregate of ...
(Date:1/15/2014)... Shire plc (LSE: SHP, NASDAQ: SHPG ... Trading (OFT) approval condition to the announced tender offer for ...   As a result of the waiver, the ... expects to complete the tender offer on January 24, 2014 ... of all of the remaining conditions to the tender offer. ...
(Date:1/15/2014)... 15, 2014 BreedIT Corp (OTC: ... worldwide distributor of highly sophisticated agro-breeding solutions for plant ... 2014, the Company,s board of directors appointed chemistry and ... its new member of the board. From ... Teva Pharmaceutical Industries Ltd (NYSE: TEVA ) ...
Breaking Medicine Technology:Celsion Corporation Announces $15 Million At-The-Market Registered Direct Offering 2Celsion Corporation Announces $15 Million At-The-Market Registered Direct Offering 3Shire Waives OFT Condition Relating to the Acquisition of ViroPharma Inc. 2Shire Waives OFT Condition Relating to the Acquisition of ViroPharma Inc. 3BreedIT (OTC: BRDT) Appoints Chemistry and Pharmaceutical Industry Expert Dr. Ben-Zion Weiner to Its Board of Directors 2BreedIT (OTC: BRDT) Appoints Chemistry and Pharmaceutical Industry Expert Dr. Ben-Zion Weiner to Its Board of Directors 3
... 2011 PDI, Inc. (Nasdaq: PDII ), a ... companies, today announced the extension of a contract sales engagement ... began April 1 and will run for the balance of ... PDI of approximately $23 million. Under the program, ...
... April 4, 2011 VIVUS, Inc. (Nasdaq: VVUS ... the investigational drug QNEXA® for two years showed reductions in ... as improvements in lipid levels following significant reductions in weight ... two years. The data – additional results ...
Cached Medicine Technology:PDI Announces Contract Extension With Revenue Value of Approximately $23 Million 2Weight Loss With QNEXA® Over Two Years Provides Patients With Substantial Cardiovascular Benefits 2Weight Loss With QNEXA® Over Two Years Provides Patients With Substantial Cardiovascular Benefits 3
(Date:4/14/2014)... dense, urban centers around the world, many people live ... tall buildings that block sunlight. And as the global ... together, the darkness will only spread. , To ... translucent panel that redirects sunlight onto narrow streets and ... over the edge at an angle, where it spreads ...
(Date:4/14/2014)... professor of chemical engineering at Virginia Tech , ... analyze living cells. The long-term goal is to gain ... In his lab , Lu and his students ... events inside cells. These devices promote high sensitivity and ... cells. , Based on their record of achievements, the ...
(Date:4/14/2014)... April 2014, Perth, Australia. Drug discovery company Proteomics ... development of a companion diagnostic (CDx) test with ... , The research team authenticated the panel of ... control samples. Seven biomarkers were validated at high ... , The mass spectrometry data was then cross-validated ...
(Date:4/14/2014)... for high-risk bladder cancer, chemotherapy before or after ... practice. The findings are published early online in ... American Cancer Society. , Clinical trials have shown ... bladder cancer who are given chemotherapy before surgery. ... surgery also improves survival. To investigate the use ...
(Date:4/11/2014)... control brain cell production could pave the way for ... Scientists have gained new understanding of the role played ... nerve and brain cells are formed a process ... healthy. Their findings could help explain what happens when ... fundamental characteristic of many diseases including cancer. , ...
Breaking Medicine News(10 mins):Health News:Let the sun shine in: Redirecting sunlight to urban alleyways 2Health News:Efficient analysis of small quantity of cells improves chances to understand disease 2
... HealthDay Reporter , THURSDAY, Sept. 16 (HealthDay News) -- ... cancer, new research finds. Prior research has shown higher ... this study is among the first to show that lower ... as gastrointestinal bleeding -- may also be effective, said Eric ...
... of fertilizer that feeds breast cancer progression, significantly ... researchers at UCLA,s Jonsson Comprehensive Cancer Center have ... the immune cells that are trying to fight ... the body against disease into aiders and abettors. ...
... By Amanda Gardner HealthDay Reporter , WEDNESDAY, ... Wednesday over whether the diet drug Meridia should be pulled ... risk of heart attack and stroke. Members of an ... said the drug should remain available to consumers called for ...
... Reporter , WEDNESDAY, Sept. 15 (HealthDay News) -- Children with ... that is, yawn in response to seeing others yawn, a ... contagion," an unconscious response that reflects a recognition of how ... and others is an important step in a child,s social ...
... WEDNESDAY, Sept. 15 (HealthDay News) -- When people with chronic ... the level of hemoglobin cells in their blood should go ... levels don,t increase by much, these "poor responders" experience a ... Reporting in the Sept. 16 issue of the New ...
... Center at the University of California, San Diego has ... the American College of Radiology (ACR). ... and this prestigious certificate recognizes our extraordinary effort," said ... Moores UCSD Cancer Center. "ACR leads the way toward ...
Cached Medicine News:Health News:Low-Dose Aspirin May Reduce Colon Cancer Risk 2Health News:Low-Dose Aspirin May Reduce Colon Cancer Risk 3Health News:Stress accelerates breast cancer progression in mice 2Health News:Stress accelerates breast cancer progression in mice 3Health News:Stress accelerates breast cancer progression in mice 4Health News:FDA Advisers Divided on Whether to Ban Diet Drug Meridia 2Health News:FDA Advisers Divided on Whether to Ban Diet Drug Meridia 3Health News:Autistic Children Don't Seem to Yawn 'Contagiously' 2Health News:Autistic Children Don't Seem to Yawn 'Contagiously' 3Health News:Anemia Drugs Could Pose Threat to Some Kidney Patients 2Health News:Anemia Drugs Could Pose Threat to Some Kidney Patients 3
... FloSeal is a prorietary combination of ... FloSeal is a high viscosity gel for ... capillary oozing to arterial spurting. FloSeal is ... to haemostasis when control of bleeding by ...
... gives you new options for skin wound ... application only to hold closed easily approximated ... including punctures from minimally invasive surgery, and ... may be used in conjunction with, but ...
... Indermil® tissue adhesive is indicated for the ... incisions, and trauma-induced lacerations in areas of ... and have easily approximated skin edges. In ... adhesive may act as a barrier to ...
... office to eliminate paper completely without ... functions. With PT Medical's digital ... add digital signatures to informed consents, ... that require a patient, doctor, or ...
Medicine Products: